genome-engineering
(4)
Joanne Smith-Farrell
Joanne Smith-Farrell is the President and CEO of Be Biopharma, a Cambridge, Massachusetts company building a new class of medicines from engineered B cells - the body's own protein factories. A physicist by training who moved into drug development, she has spent more than 25 years leading teams tackling cancer and rare diseases, most notably building bluebird bio's 400-person oncology cell therapy business behind the CAR-T therapy Abecma. Since taking the helm at Be Bio in early 2021, she has steered the company through more than $350 million in funding as it works to turn B cells into durable, in vivo sources of therapeutic proteins.
Geoffrey von Maltzahn
Geoffrey von Maltzahn is the co-founder and CEO of Lila Sciences, a Cambridge company building what it calls scientific superintelligence: AI plus robotic labs that run the scientific method autonomously. A general partner at Flagship Pioneering, he has founded or co-founded a string of companies including Generate:Biomedicines, Tessera Therapeutics, Indigo Agriculture, Sana Biotechnology, Seres Therapeutics and Quotient Therapeutics, which together carry more than $10 billion in market value. He holds a PhD from the Harvard-MIT Division of Health Sciences and Technology and is named on more than 200 patents.
Eric Abbate
Eric Abbate is a synthetic-biology scientist turned CEO who led Solar Biotech, a Virginia-based startup building solar-powered, water-neutral fermentation plants to make biodesigned cosmetics, food ingredients and bioelectronic components. A UC Berkeley-trained molecular and cell biologist, he ran high-throughput genome-engineering and analytical biochemistry teams at Inscripta and was corresponding author on a widely cited paper on optimizing strain engineering for industrial-scale production. He steered Solar Biotech from lab science toward a modular 'BioNodes' manufacturing model before the company entered Chapter 11 in 2024 with plans to sell its assets and reboot.
Marc Lajoie
Marc Lajoie is a protein designer turned biotech CEO. He co-founded Outpace Bio in 2021 in Seattle, where he is chief executive, building engineered cell therapies that aim to bring the kind of cures seen in blood cancers to the solid tumors that make up the vast majority of cancer cases. Trained in George Church's genome-engineering lab at Harvard and David Baker's Institute for Protein Design at the University of Washington, Lajoie helped pioneer the design of proteins with moving parts - molecules that compute, switch, and make decisions inside living cells. Outpace raised a $144M oversubscribed Series B in 2024 to push its AI-powered, protein-designed therapies toward the clinic.